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Background: The increasing resistance of Candida yeasts towards antifungal compounds and the limited choice of
therapeutic drugs have spurred great interest amongst the scientific community to search for alternative anti-Candida
compounds. Mycocins and fungal metabolites have been reported to have the potential for treatment of fungal
infections. In this study, the growth inhibition of Candida species by a mycocin produced by Wickerhamomyces
anomalus and a lactone compound from Aureobasidium pullulans were investigated.
Methods: Mycocin was purified from the culture supernatant of an environmental isolate of W. anomalus using
Sephadex G-75 gel filtration column chromatography. The mycocin preparation was subjected to SDS-PAGE analysis
followed by MALDI TOF/TOF mass spectrometry analysis. The thermal and temperature stability of the mycocin were
determined. The glucanase activity of the mycocin was investigated by substrate staining of the mycocin with
4-methyl-umbelliferyl-ß-D-glucoside (MUG). Gas chromatography mass spectrometry (GCMS) analysis was used to
identify anti-Candida metabolite in the culture supernatant of an environmental isolate of Aureobasidium pullulans.
The inhibitory effects of the anti-Candida compound against planktonic and biofilm cultures of various Candida species
were determined using broth microdilution and biofilm quantitation methods.
Results: A mycocin active against Candida mesorugosa but not C. albicans, C. parapsilosis and C. krusei was isolated
from the culture supernatant of W. anomalus in this study. The mycocin, identified as exo-ß-1,3 glucanase by MALDI
TOF/TOF mass spectrometry, was stable at pH 3–6 and temperature ranging from 4-37°C. The glucanase activity of the
mycocin was confirmed by substrate staining with MUG. 5-hydroxy-2-decenoic acid lactone (HDCL) was identified from
the culture supernatant of A. pullulans. Using a commercial source of HDCL, the planktonic and biofilm MICs of HDCL
against various Candida species were determined in this study.
Conclusions: W. anomalus mycocin demonstrated a narrow spectrum of activity targeting only against C. mesorugosa,
while HDCL demonstrated a broad spectrum of inhibitory action against multiple Candida species. The growth
inhibition of W. anomalus mycocin and the lactone compound from A. pullulans against Candida yeasts should be
further explored for therapeutic potentials against candidiasis.
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Mycocinogenic or “killer” yeasts secrete proteinaceous
mycocins (also known as killer toxins) that are lethal
to other yeast strains but to which the producing
yeasts are immune [1,2]. Since the first discovery of
killer toxin-secreting strains of Saccharomyces cerevi-
siae [3], yeast killer phenomenon has been docu-
mented in many different yeast species and genera
from the environment, including Wickerhamomyces
anomalus (previously known as Pichia anomala and
Hansenula anomala) and Aureobasidium pullulans
[4-9]. Both yeasts have been reported to have many
applications in food fermentation, biocontrol and pro-
duction of therapeutic molecules [7,10]. The antifun-
gal activity of W. anomalus has been associated with
glucanase-induced lysis [7], while the production of
many metabolites, enzymes and antibiotics by A.
pullulans has been important for its biocontrol activ-
ity [10].
Candida is a medically important yeast pathogen
which causes mucocutaneous and life-threatening sys-
temic infections in susceptible individuals. Recent inves-
tigation based on molecular approach suggests that the
genus is not monophyletic, and the relationships among
various Candida species are not clearly resolved [11].
Amongst the Candida species, Candida albicans is the
most predominant cause of candidiasis; however, the in-
cidence of infections caused by non-albicans Candida
species such as C. rugosa species complex has also in-
creased [12,13].
Candidiasis is usually associated with biofilm forma-
tion on the indwelling medical devices. Biofilms cells
are embedded within an extracellular matrix and are
difficult to treat as the cells are significantly more
resistant to antimicrobial agents [14,15]. Several myco-
cins have been reported to have the potential for treat-
ment against fungal infections including candidiasis
[16-18]. Additionally, microbial metabolites such as etha-
nol, isoamyl alcohol, 2-phenylethanol, 1-dodecanol, E-
nerolidol, glycolipid biosurfactant and signalling molecules
secreted in the yeast culture filtrates have been known to
affect the growth of C. albicans biofilm [19,20]. For in-
stance, farnesol is a quorum-sensing molecule which in-
hibits pseudohyphae transition and biofilm formation in
C. albicans [21,22].
Due to the increasing resistance of Candida towards
antifungal compounds and the limited choice of thera-
peutic drugs, searching for new antifungal compound is
necessary. W. anomalus and A. pullulans with mycoci-
nogenic activity have been isolated from fermented food
and the natural environment in our study recently [8,9].
Herein, we describe our investigation on the growth in-
hibition of Candida species by W. anomalus mycocin
and a lactone compound from A. pullulans.Methods
Yeasts and assessment of mycocin activity
W. anomalus strain tp2-15 and A. pullulans strain L7-10
isolated from fermented tapioca and a plant leaf, respect-
ively, from two previous studies were used in this study
[8,9]. Identification of yeast strains was performed by se-
quence analysis of the yeast internal transcribed spacer
(ITS) regions. Analysis using BLAST (Basic Local Align-
ment Search Tool) at NCBI database revealed 100% se-
quence similarities of the strain tp2-15 with W. anomalus
strain MUCL 51259 from Belgium (585/585 nucleotides,
Genbank accession no. FN394001) [23]. The strain tp2-15
differed in 1 nucleotide (gap) compared to the type strain
of W. anomalus (AY046221). The strain L7-10 showed
100% sequence similarity with that of A. pullulans isolate
BK6 from Thailand (574/574 nucleotides, Genbank acces-
sion no. AY225164) [24]. Queries at ISHAM ITS database
(http://its.mycologylab.org/) show that the sequence of
strain tp2-15 was 100% similarity with several W. anomalus
reference sequences (MITS501, 502, 492, 490, 511, 520,
513–516) in the database, while the sequence of strain L7-
10 was most identical (99.827% similarity, 1 gap) with the
reference sequence of a A. pullulans strain (MITS374). ITS
sequence of the strain L7-10 showed 99% similarity to the
neotype strain of A. pullulans var. pullulans (FJ150906),
99% similarity to the type strain of A. pullulans var. nami-
bae (FJ150875), 99% similarity to the type strain of A. pullu-
lans var. melanogenum (FJ150886) and 98% similarity to
the type strain of A. pullulans var. subglaciale (FJ150895).
The closest match among the type strains (6 substitutions)
was observed with the neotype strain of A. pullulans var.
pullulans and the neotype strain of A. pullulans var.
namibae.
The sensitivity strains used for assessment of mycocino-
genic activity in this study were C. albicans ATCC 90028,
C. parapsilosis ATCC22019 and C. krusei ATCC6258. Add-
itionally, due to the unavailability of reference strains, clin-
ical cultures of C. dubliniensis (designated as strain 2879)
[25] and a member of C. rugosa species complex (desig-
nated as 3209, Genbank accession no. HM641831) [26]
were also used. According to the recent reassessment of the
C. rugosa species complex, the strain 3209 has been re-
identified as C. mesorugosa [13].
A well diffusion assay was used for assessment of the
mycocin activity, as described previously [8,9]. Briefly,
overnight cultures of sensitive strain were suspended in
sterile distilled water to obtain about 105 cells/ml (80%
transmittance at 530 nm followed by 10X dilution). The
yeast suspension was spread using a sterile swab on a
YEPD-MB agar plate. Yeasts were then point-inoculated
in duplicate on the agar plate. The plate was incubated at
30°C for 72 h and inspected daily for the appearance of in-
hibition zone surrounding the inoculated area as an indi-
cation of mycocinogenic activity.
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only against C. rugosa complex as demonstrated in the
previous study [8], the same strain (3209) was used as a
sensitive strain for subsequent study. For testing of anti-
Candida metabolite from A. pullulans, C. albicans refer-
ence strain SC5314 was used for assessment of A. pullu-
lans metabolites in the study. Additionally, a total of 92
clinical isolates from various Candida species were used
to investigate the inhibitory effects using broth microdilu-
tion and biofilm quantitation methods. The isolates
included C. glabrata (n =26), C. krusei (n =17), C. albicans
(n =15), C. parapsilosis (n =8), C. tropicalis (n =10), C.
orthopsilosis (n =8), C. rugosa species complex (n =5), C.
dubliniensis (n =1), Meyerozyma guilliermondii (n =1) and
C. metapsilosis (n =1). These isolates had been identified
using API 20C AUX system (bioMerieux, Marcy, l’Etoile,
France) or sequence analysis of their ITS gene regions
prior to susceptibility testing.
Isolation and purification of W. anomalus mycocin
Strain tp2-15 was cultivated in YEPD broth (1000 ml)
buffered with 50 mM sodium phosphate citric acid
(pH 4.5) at 30°C and 120 rpm in a gyratory shaker (Stuart,
UK) for 3 days. The culture supernatant was filtered
through a 0.22 μm filter system (Sartorius, Germany) and
added with ice-cold ethanol (Fisher Scientific, USA) to a
final concentration of 70% (v/v). The mixture was then in-
cubated at −20°C for 1 h and centrifuged at 12,000 rpm at
4°C for 45 min. The pellet was resuspended in 10 ml of
50 mM sodium phosphate citric acid buffer (pH 4.5) in-
corporated with 20% glycerol and filtered. For determin-
ation of pH stability, mycocin samples were prepared in
50 mM sodium phosphate citric acid buffered at different
pHs (ranging from 3 to 6). The mycocin activity was
assessed by a well diffusion assay as described above ex-
cept that the samples were pipetted into wells of approxi-
mately 10 mm in diameter in the YEPD-MB agar plate.
For thermal stability study, mycocin samples were buff-
ered at pH 4.5 and incubated at different temperatures: 4,
25, 30, 37, 50, 70 and 100°C for 1 h before the mycocin ac-
tivity was assessed.
For purification of the mycocin, Sephadex G-75 gel
slurry (product code: 17-0050-01, lab packs, GE health-
care, USA) in 50 mM sodium phosphate citric acid buffer
(pH 4.5) was packed into a column of 1.8 cm (diameter) ×
100 cm (length) to 80 cm in length and equilibrated with
the same buffer at a rate of 1 ml/min. Seven milliliters of
the above mycocin preparation were then loaded onto a
Sephadex G-75 gel-filtration column. Elution was per-
formed using the same buffer at a flow rate of 1 ml/min at
4°C. Fractions of 2 ml were collected and filtered through
0.2 μm pore size filters (Sartorius, Germany) for mycocin
testing. The presence of protein in the fractions was deter-
mined by measuring the UV absorbance (at 280 nm) usinga Nanophotometer™ (Implen GmbH, Germany). Fractions
with mycocin activity were pooled and concentrated using
a 10 kDa-cut off ultrafilter (Vivaspin 20, Sartorius,
Germany). The mycocin activity was determined using a
microplate assay as described by Hodgson et al. [16].
Briefly, 100 μl mycocin preparation was mixed with equal
volume of C. mesorugosa cell suspension pre-adjusted to
105 cells/ml in RPMI 1640 medium (Sigma-Aldrich, USA)
in a microtiter well and incubated at 30°C for 24 h. Yeast
growth was determined by measuring OD450 using a mi-
croplate reader (Glomax, Promega, USA). Mycocin activ-
ity was expressed as the percentage growth inhibition of
the sensitive strain compared to a mycocin-free control
(i.e. 50 mM sodium phosphate citric acid buffer, pH 4.5).
SDS-PAGE was performed according to Laemmli [27]
using a concentrated sample from the active fractions in
a mini-PROTEAN® Tetra Cell electrophoresis system
(Biorad, USA) A 4% (w/v) acrylamide was used in the
stacking gel and 10% (w/v) acrylamide was used in the
resolving gel. After electrophoresis, the protein was
stained with Coomassie brilliant blue R-250 (Sigma-
Aldrich, USA) and the molecular mass was determined
by comparison with known marker proteins (Fermentas,
Lithuania). The protein fragments in the SDS-PAGE gel
was identified by MALDI TOF/TOF mass spectrometry
(Proteomics International, Australia) using a 5800 Prote-
omics Analyzer (AB Sciex, USA).
Discontinuous Native PAGE was performed to detect
glucanase activity from the active fractions as described by
Nebrada et al. [28]. After electrophoresis, the native gel
was incubated with 0.2% 4-methyl-umbelliferyl-ß-D-glu-
coside (MUG) (Sigma-Aldrich: M-3633, USA) in 50 mM
acetate buffer (pH 5.0) at 30°C for 45 min. Protein with
glucanase activity will be visualized as a fluorescence band
on a UV transilluminator (Syngene, UK).
Isolation and identification of a lactone compound from
A. pullulans
Strain L7-10 was cultured in a broth containing 0.67% (w/v)
yeast nitrogen base medium supplemented with 2% (w/v)
glucose at 30°C with agitation (120 rpm) for seven days. The
culture broth was then separated from the biomass by cen-
trifugation at 4000 rpm for 30 min and filtered through a
0.22 μm filter membrane (Sartorius Stedim Biotech GmbH,
Germany). A total of 12 liters of culture filtrate was ex-
tracted three times with ethyl acetate before fractionating
using a 40 × 100 mm Prep Nova-Pak HR C18 column (Wa-
ters Co., Milford, MA, USA) in a Prep-HPLC system.
Twelve fractions (A to L) were collected and each fraction
was adjusted to 1 mg/ml prior to testing using a biofilm
quantitation method [9].
The identification of compound in the active fractions was
performed using Shimadzu GC-17A gas chromatography,
GCMS-QP5050A mass spectrometer and a capillary
ba
Figure 1 Killer activity by (a) cultures of W. anomalus killer yeast and (b) an ethanol-precipitated mycocin sample, against C.
mesorugosa on a YEPD-MB agar plate.
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eter). GC-MS was performed using splitless injection with
the following setting: injector at 250°C, column at 50°C,
heating ramp of 5°C/min, final temperature of 300°C, and














































Figure 2 Determination of the effect of (a) pH and (b) temperature ongas at 1.4 ml/min. The GC-MS electron ionization system
was set at 70 eV. Identification of active compound was
made by comparison with the database from WILEY 229
library of mass-spectra, National Institute of Standards
and Technology (NIST) 107 and NIST 21.3.5 4 4.5 5 5.5 6 6.5 7
pH 
70 80 90 100 110
 (ºC)
the activity of W. anomalus mycocin.
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pound for testing, 5-hydroxy-2-decenoic acid lactone
(abbreviated as HDCL, CAS no: 54814-64-1) was ob-
tained from Penta International Corp., Livingston, USA.
A stock solution of HDCL was prepared at 450 mg/ml
in DMSO (AMRESCO, Cleveland, Ohio, USA). For de-
termination of the susceptibility of 92 isolates of various
Candida species, final concentrations of HDCL ranging
from 8 to 4096 μg/ml were prepared in RPMI 1640
broth medium with L-glutamine, without bicarbonate
(Sigma Aldrich, USA), and buffered with MOPS
medium (pH 7.0). The MICs of the isolates were deter-
mined by broth microdilution method as in accordance
to CLSI method (2008).
The biofilm MIC of the isolates was determined as de-
scribed by Melo et al. [29]. Briefly, an overnight yeast
culture was suspended in RPMI 1640 broth medium
supplemented with L-glutamine and buffered with
MOPS (Sigma, USA) and adjusted to 107 cells/ml
(OD530nm = 0.38) prior to use. One hundred microliters
























Figure 3 Determination of the mycocin activity of fractions eluted fro
microplate assay (a): the highest growth inhibition against C. mesorug
peak (P); and well diffusion assay (b): 1, void sample; 2, ethanol-preciwell of a flat-bottomed, 96-well polystyrene micro-
titer plate. After incubation under shaking condition
(75 rpm) at 37°C for 1.5 h, unattached cells were re-
moved by washing twice with 150 μl phosphate-buffered
saline (PBS). Fresh RPMI 1640 medium (100 μl) was
then added to the microtiter well to allow proliferation
of the biofilm for 24 h. The biofilm cells were washed
once with PBS before exposure to 100 μl of HDCL
solutions (final concentration ranging from 8 to
4096 μg/ml). The metabolic activity of biofilms after
48 hours of exposure to HDCL was assessed using XTT
reduction assays as described by Jin et al. [30]. Briefly,
the biofilm in each well was washed twice with 200 μl PBS
before adding with a solution containing 2,3-bis(2-meth-
oxy-4-nitro-5-sulfophenyl)-5-(phenylamino)carbonyl)-2H-
tetrazolium hydroxide (XTT) with menadione. The ab-
sorbance of the resultant solution (100 μl) after incubation
for 1 h in the dark was measured using a spectrophotom-
eter at 492 nm. The biofilm MIC of each Candida isolate
was determined on the basis of a 50% reduction in meta-
















m Sephadex gel filtration column against C. mesorugosa by
osa was shown in fraction 8 which corresponded with a protein
pitated mycocin sample; 3 to 10, 1 to 8 eluted fractions.
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were performed in duplicate.
Results
Isolation and identification of W. anomalus mycocin
Figure 1 shows the inhibitory effects of W. anomalus cul-
ture and the ethanol-precipitated mycocin preparation
against C. mesorugosa (strain 3209) using well diffusion
assay on a YEPD-MB agar plate. Clear zone of inhibition
(about 2–3 mm from the edge to the colony/well) was
observed for both W. anomalus culture and the ethanol-
precipitated mycocin preparation after 2 days of incubation.
Figure 2 shows that the mycocin was active at pH 3–6
when incubated at 30°C. The mycocin activity was detected
when incubated at 4, 25, 30 and 37°C, but no activity was
detected beyond 50°C. A total of 30 fractions were eluted
from the Sephadex G-75 gel column for determination of
mycocin activity. Fraction 8 demonstrated the highest
growth inhibition against the yeast by microplate assay
(Figure 3a) and well diffusion assay (Figure 3b).1 2 3
Figure 4 A fluorescent activity band was observed in the
ethanol-precipitated culture supernatant of three batches of W.
anomalus, indicating the presence of ß-1,3-glucanase activity
(Lane 1 to 3). ß-1,3-glucanase activity was detected by overlaying
the native gel with 0.2% (wt/vol) MUG in acetate buffer (pH 5) and
incubating for 45 min at 30°C before UV illumination.
b
c
Figure 5 The effects of (a) fraction J (b) fraction K derived from
culture supernatant of A. pullulans on the biofilm development of
C. albicans reference strain SC5314 (yeast cells were co-incubated
with crude extract and allowed to proliferate for 24 h) (c) negative
control (normal growth medium was used instead of crude
extract).
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revealed four major protein fragments (data not shown).
Mass spectrometry analysis demonstrated the identifica-
tion of two fragments (45 kDa and 50 kDa) as exo-ß-
1,3-glucanase. Both fragments demonstrated the closest
match to that of the glucanase derived from a marine
yeast, P. anomala YF07b (A0MPR7) which inhibited the
growth of Metschnikowia bicuspidata, a pathogenic yeast
causing milky disease in crab [31]. A peptide sequence of
GDYWDYQND KIR was detected from the fragment with
the molecular weight of 45 kDa, while three matching
peptides (GDYWDYQND KIR, LNDFWQQGYHNLR
and WLNGVGR) were detected from the fragment with
the molecular weight of 50 kDa. MUG staining of native
gel with the mycocin samples showed the presence ofFigure 6 GC-MS analysis of the chemical structure and mass spectrum
pullulans culture extract.fluorescent activity bands, indicating the association of glu-
canase activity with theW. anomalus mycocin (Figure 4).
Isolation and purification of lactone compound from A.
pullulans
Only two fractions (J and K) exhibited inhibitory effect
against biofilm cultures of C. albicans. Microscopic ana-
lysis showed inhibition of hyphal extension by fractions J
and K, whereas extensive hyphal filaments were ob-
served for the negative control (untreated cells) after
72 h of incubation (Figure 5). GC-MS analysis revealed
the presence of 5-hydroxy-2-decenoic acid lactone (95%
match, Figure 6) in the fraction K. The lactone com-
pound is characterized by a closed ring containing two
or more carbon atoms and a single oxygen atom, with aof the major compounds present in the fraction K of A.
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other oxygen.
Table 1 shows the susceptibility profiles of Candida
isolates to the commercial source of 5-hydroxy-2-dece-
noic acid lactone (abbreviated as HDCL). The planktonic
MICs range, MIC50 and MIC90 of HDCL against the iso-
lates were 64 to 256 μg/ml, 256 μg/ml and 256 μg/ml,
respectively. Compared to other isolates, Candida
parapsilosis isolates showed the lowest MIC50 values
(64 μg/ml). The planktonic MIC50 and MIC90 of non-
albicans Candida species including Candida krusei,
C. glabrata, C. parapsilosis, C. tropicalis, C. orthopsilosis
and C. rugosa species complex were 256 μg/ml. The bio-
film MIC range, MIC50 and MIC90 of the Candida
yeasts were 64 to 1024 μg/ml, 256 μg/ml and 512 μg/ml,
respectively (Table 1). Compared to other species,
Candida krusei, C. parapsilosis and C. orthopsilosis iso-
lates exhibited the lowest MIC50 values (128 μg/ml). The
overall biofilm MIC50 and MIC90 of non-albicans
Candida species were both 256 μg/ml.
Discussion
Research in mycocinogenic yeasts has improved our un-
derstanding on the eukaryotic cell biology, host-virus
interaction and the mechanisms of eukaryotic secretion
pathway [2,3,5,6]. W. anomalus (previously known as P.
anomala) producing anti-Candida toxins have been re-
ported in several studies [32-34]. In this study, the protein
isolated from W. anomalus exhibited basic characteristics
of mycocin with pH 3–6 and temperature ranging from 4
to 37°C. Additionally, the mycocin was identified as exo-Table 1 In vitro susceptibilities of Candida isolates to a stand
Candida spp. Planktonic MIC (μ
MIC range MIC50
Candida albicans ( n = 15) 128 - 256 256
Nonalbicans Candida species (n = 77) 64 - 256 256
Candida glabrata (n = 26) 64 - 256 256
C. krusei (n = 17) 128 - 256 128
C. parapsilosis (n = 8) 64 - 256 64
C. tropicalis (n = 10) 64 - 256 128
C. orthopsilosis (n = 8) 128 - 256 256
C. rugosa species complex (n = 5) 128 - 256 128
C. dubliniensis (n =1) 128 ND
M. guelliermondii (n =1) 128 ND
C. metapsilosis (n =1) 256 ND
All isolates (n = 92) 64 - 256 256
Footnote: Planktonic MIC: The lowest concentration of HDCL required to inhibit yea
Biofilm MIC: The lowest concentration of HDCL required to cause 50% reduction in
MIC50 and MIC90 values were only calculated for those species with 5 or more isola
ND: Not determined.
a, b, c: Five Candida glabrata and two each of C. parapsilosis and C. orthopsilosis isola
formation (OD490nm < 0.1).ß-1,3 glucanase by mass spectrometry analysis and its ac-
tivity was confirmed by MUG staining.
Glucanase is produced by yeasts to facilitate morpho-
genesis and recycling of cell wall components [35,36].
Table 2 summarizes the features of mycocins derived
from four P. anomala strains (WC65, NCYC 432, 434,
YF07b) which had been purified by various chromatographic
methods [34,37,38]. All mycocins were active at low pH.
The mycocin for WC65 strain had the highest molecular
weight (83.3 kDa) compared to others [37,38]. The mycocin
isolated from this study shared similar characteristics (pH,
temperature and molecular weight) as those reported for
NCYC 432, 434, YF07b strains [37,38]. However, unlike
other mycocins from P. anomala NCYC 434 and WC 65
which demonstrated inhibition against the growth of C. albi-
cans, the mycocin investigated in this study was not inhibi-
tory to C. albicans, instead, it was found to be only active
against C. mesorugosa.
The different killer pattern of W. anomalus mycocin
could be attributed to the specificity of glucanases which
have selective preference for different types of glycosidic
linkages and glucan receptors of the sensitive yeast strains
[6,39-41]. Several investigators have proposed the use of
mycocin for clarification of the taxonomy of closely related
organisms [33,42]. Recently, C. rugosa has been differenti-
ated to separate clade from other pathogenic Candida spe-
cies including C. albicans, C. tropicalis, C. parapsilosis,
based on multigene analyses [11]. Hence, the finding on the
killer pattern of W. anomalus mycocin may reflect the dif-
ferent levels of taxonomic organization of this organism
when compared to C. albicans.ard preparation of HDCL
g/ml) Biofilm MIC (μg/ml)
MIC90 MIC range MIC50 MIC90
256 128 - 512 256 256
256 64 - 1024 256 256
256 64 - 512a 256a 512a
256 64 - 256 128 256
256 128 - 1024b 128b 1024b
256 256 - 1024 256 512
256 128 - 256c 128c 256c
256 128 - 512 512 512
ND 256 ND ND
ND 128 ND ND
ND 128 ND ND
256 64 - 1024 256 512
st growth after incubation at 37°C for 48 h.
biofilm metabolic activity after incubation at 37°C for 48 h.
tes.
tes were excluded from the study due to poor biofilm
Table 2 Source and features of W. anomalus mycocins
W. anomalus
strain
WC 65 [34] NCYC 434 [37] NCYC 432 [38] YF07b [31] tp2-15 (isolated
in this study)
Source Culture collection Culture collection Culture collection Marine-
derived
Fermented tapioca
pH stability 2 to 5 3 to 5.5 3 to 5.5 3 to 5 3 to 6
Temperature
stability (°C)
Not determined Up to 37 Up to 37 20-90 4 to 37
Molecular
weight (kDa)
83.3 49 47 47 45, 50
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ing fungal infections [5,16-18,42]. The fact that the tar-
get molecule for mycocin (glucan as for W. anomalus
mycocin in this study) is absent in mammalian cells,
suggests its potential application against fungal infec-
tions on the skin and mucosal membranes, as most
mycocins are not suitable for oral or intravenous use,
due to their sensitivity to proteinase degradation, antige-
nicity, and activity within a narrow pH range [42]. How-
ever, development of anti-idiotypic antibodies which
share the active site of the mycocin and possess antifun-
gal activity is possible [5,18].
In this study, a lactone compound (5-hydroxy-2-dece-
noic acid lactone) inhibiting various Candida species
was isolated from an ethyl-acetate extract of the culture
supernatant of A. pullulans. Lactone is an analogue of
6-pentyl-2H-pyran-2-one (synonym: massoialactone),
which has been reported as a byproduct of Trichoderma
[43]. Some specific isolates of Aureobasidium also pro-
duced large amounts of delactonised massoialactone as
an extracellular ester [44]. In vitro biological activity of
massoialactone-related compounds against phytopatho-
gens and human pathogens including C. albicans has
been reported [43,45]. Several lactone compounds have
been reported to be effective at preventing biofilm for-
mation of bacteria or fungi. For instance, plant sesqui-
terpene lactones are inhibitory to the biofilm growth of
P. aeruginosa [46] and 3-oxo-C12 homoserine lactone
(3-oxo-C12-HSL) is inhibitory to C. albicans filamenta-
tion by blocking the yeast-to-hyphal switch [47]. Unlike
amphotericin, azoles and caspofungin which target at
the fungal cell wall, the antimicrobial mechanism
responsible for massoialactone activity against C. albi-
cans is probably through the inhibition of the fungal re-
spiratory system [44]. However, data is limited as therehas been no detail study on the use of the lactone com-
pound against Candida yeasts.
HDCL demonstrated a broad spectrum of inhibitory ac-
tion against multiple Candida species in this study. How-
ever, a high concentration of HDCL (at least 64 μg/ml)
was required to inhibit both planktonic and biofilm
cultures of Candida yeasts. In our previous study, the
amphotericin and fluconazole MIC50 against a culture col-
lection of Malaysian clinical isolates of C. albicans and
non-albicans Candida species were 0.25 and 2 μg/ml,
respectively [48]. An increased resistance of Candida bio-
film cultures to amphotericin (more than 32 folds) and
fluconazole (≥128 μg/ml) as compared to their planktonic
counterparts was also reported in that study. In this study,
there was no obvious difference in the HDCL MICs of
both planktonic and biofilm cultures of Candida yeasts
(Table 1).
Conclusion
The growth inhibition of W. anomalus mycocin and 5-
hydroxy-2-decenoic acid lactone from A. pullulans against
Candida yeasts should be further explored for biotechno-
logical applications and therapeutic potentials. Pathogenic
fungi such as Aspergillus and dermatophytes may be in-
cluded for future testing to broaden the spectrum of
mycocin and the lactone compound. As little is known
about yeast killing phenomena and mechanisms of ac-
tions, proteome profiling and gene expression studies of
Candida in response to these molecules will be required.
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